Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00124982
Status:
COMPLETED
Last Update Posted:
2012-02-27
First Post:
2005-06-30
Brief Title:
Study of Abatacept BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS Disease Modifying Antirheumatic Drugs Who Have an Inadequate Response to Anti-TNF Therapy
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase III Multi-Center Open Label Study to Evaluate the Efficacy Tolerability and Safety of Abatacept BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs DMARDs approved for rheumatoid arthritis RA in subjects with active RA Secondary objectives assessed the clinical efficacy of combination treatment including disease activity physical function and quality of life outcomes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None